MX390756B - Célula t asesina universal - Google Patents

Célula t asesina universal

Info

Publication number
MX390756B
MX390756B MX2017009459A MX2017009459A MX390756B MX 390756 B MX390756 B MX 390756B MX 2017009459 A MX2017009459 A MX 2017009459A MX 2017009459 A MX2017009459 A MX 2017009459A MX 390756 B MX390756 B MX 390756B
Authority
MX
Mexico
Prior art keywords
cells
modified
universal
immunogenic
cell
Prior art date
Application number
MX2017009459A
Other languages
English (en)
Spanish (es)
Other versions
MX2017009459A (es
Inventor
Else Marit Inderberg Suso
Gunnar Kvalheim
Gustav Gaudernack
Sébastien Wälchli
Original Assignee
Univ Oslo Hf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oslo Hf filed Critical Univ Oslo Hf
Publication of MX2017009459A publication Critical patent/MX2017009459A/es
Publication of MX390756B publication Critical patent/MX390756B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4225—Growth factors
    • A61K40/4229—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4246—Telomerase or [telomerase reverse transcriptase [TERT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2017009459A 2015-01-23 2016-01-22 Célula t asesina universal MX390756B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1501175.2A GB201501175D0 (en) 2015-01-23 2015-01-23 A universal T-cell for personalised medicine
PCT/EP2016/051344 WO2016116601A1 (en) 2015-01-23 2016-01-22 Universal killer t-cell

Publications (2)

Publication Number Publication Date
MX2017009459A MX2017009459A (es) 2018-04-11
MX390756B true MX390756B (es) 2025-03-04

Family

ID=52673865

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009459A MX390756B (es) 2015-01-23 2016-01-22 Célula t asesina universal

Country Status (17)

Country Link
US (2) US11155786B2 (OSRAM)
EP (2) EP4095239A1 (OSRAM)
JP (1) JP6899333B2 (OSRAM)
KR (1) KR102479118B1 (OSRAM)
CN (1) CN107250351A (OSRAM)
AU (2) AU2016208475B2 (OSRAM)
CA (1) CA2973924C (OSRAM)
DK (1) DK3247791T3 (OSRAM)
EA (1) EA201791381A1 (OSRAM)
ES (1) ES2922231T3 (OSRAM)
GB (1) GB201501175D0 (OSRAM)
IL (1) IL253464B (OSRAM)
MX (1) MX390756B (OSRAM)
PL (1) PL3247791T3 (OSRAM)
PT (1) PT3247791T (OSRAM)
SG (1) SG11201705693XA (OSRAM)
WO (1) WO2016116601A1 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201501175D0 (en) * 2015-01-23 2015-03-11 Univ Oslo Hf A universal T-cell for personalised medicine
DK3298033T4 (da) 2015-05-18 2023-10-02 Tcr2 Therapeutics Inc Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner
EP3452580B1 (en) * 2016-05-02 2023-08-16 Cerus Corporation Compositions and methods for improved nk cell therapies
JP7109789B2 (ja) 2016-08-02 2022-08-01 ティーシーアール２ セラピューティクス インク． 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
CA3036745A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
US20190358263A1 (en) 2016-12-07 2019-11-28 Oslo Universitetssykehus Hf Compositions and Methods for Cell Therapy
EP3565565A4 (en) * 2017-01-04 2020-12-09 Nova Southeastern University NATURAL KILLER CELLS (NK) EXPRESSING AN ANTIGEN-SPECIFIC FUNCTIONAL T-LYMPHOCYTE RECEPTOR COMPLEX (TCR), THEIR PRODUCTION METHODS AND THEIR THERAPEUTIC USE METHODS
GB201803178D0 (en) 2018-02-27 2018-04-11 Univ Oslo Hf Specific binding molecules for htert
JP7429222B2 (ja) * 2018-08-31 2024-02-07 アンヴェクティ エスアー Ｃａｒの機能を評価する方法
EP3941490A4 (en) * 2019-03-20 2023-01-04 2seventy bio, Inc. ADOPTIVE CELLULAR THERAPY
JP6977969B2 (ja) * 2019-03-22 2021-12-08 株式会社ガイアバイオメディシン 免疫細胞提供システム
EP3750547A1 (en) 2019-06-13 2020-12-16 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Modified nk-92 cells, and therapeutic and diagnostic uses thereof
CA3148127A1 (en) 2019-07-29 2021-02-04 Massachusetts Institute Of Technology Synthetic hydrogels for organogenesis
CN111662871A (zh) * 2020-06-11 2020-09-15 福建医科大学孟超肝胆医院(福州市传染病医院) 一种核酸适体功能化nk细胞及其制备与应用
JP2023542230A (ja) 2020-09-24 2023-10-05 メディジーン イミュノテラピーズ ゲーエムベーハー Ｐｒａｍｅ特異的ｔ細胞受容体およびその使用
JP2023547695A (ja) * 2020-11-03 2023-11-13 ハンチョウ キハン バイオテック カンパニー リミテッド 増強された免疫療法のためのシステムおよび方法
GB202017873D0 (en) 2020-11-12 2020-12-30 Olso Unversitetssykehus Hf Method of determining DLBCL prognosis
WO2022250312A1 (ko) * 2021-05-27 2022-12-01 (주)에스엠티바이오 신경내분비종양의 치료용 자연살해세포
US20250170175A1 (en) 2021-09-21 2025-05-29 Oslo Universitetssykehus Hf Binding proteins for terminal deoxynucleotidyl transferase (tdt)
TW202325844A (zh) * 2021-11-03 2023-07-01 中國大陸商杭州啟函生物科技有限公司 增強免疫療法的系統和方法
CN119744173A (zh) * 2022-07-22 2025-04-01 得克萨斯大学体系董事会 用于过继免疫疗法的具有增强功能的表达cd3的自然杀伤细胞
WO2024261045A1 (en) 2023-06-20 2024-12-26 Zelluna Immunotherapy As Methods of enhancing or modifying nk cells

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124251A (en) 1990-01-31 1992-06-23 Becton, Dickinson And Company CD3 ζ co-associated complex on CD16- NK cells
EP1007630B1 (en) 1997-04-30 2006-04-19 Hans Klingemann Natural killer cell lines and methods of use
IL127142A0 (en) 1998-11-19 1999-09-22 Yeda Res & Dev Immune cells having predefined biological specificity
EP1470159B1 (en) 2001-12-04 2013-08-07 Dana-Farber Cancer Institute, Inc. Antibody to latent membrane proteins and uses thereof
WO2006023148A2 (en) * 2004-07-10 2006-03-02 Fox Chase Cancer Center Genetically modified human natural killer cell lines
WO2006050270A2 (en) * 2004-11-02 2006-05-11 The Government Of The United States Of America As Represented By The Secretary Department Of Health & Human Services Compositions and methods for treating hyperproliferative disorders
US8518697B2 (en) 2006-04-04 2013-08-27 Washington University Single chain trimers and uses therefor
CN101631138A (zh) 2008-07-18 2010-01-20 深圳富泰宏精密工业有限公司 个人信息代理系统及方法
US8785601B2 (en) * 2009-01-28 2014-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
WO2013126785A1 (en) * 2012-02-22 2013-08-29 Ingenium Biotherapy Corporation A system for immunotherapy targeting tumor propagation and progression
ES2871349T3 (es) 2012-09-04 2021-10-28 Inven2 As Expansión selectiva y controlada de células NK educadas
SG11201505858VA (en) 2013-01-28 2015-09-29 St Jude Childrens Res Hospital A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
WO2014121264A1 (en) 2013-02-04 2014-08-07 Roger Williams Medical Center Methods and compositions for treating gastrointestinal stromal tumor(gist)
JP6425301B2 (ja) 2014-05-29 2018-11-21 国立大学法人富山大学 Ｔｃｒの細胞傷害活性誘導能を評価するためのｎｋ細胞株、およびその作製方法
CA2951355C (en) 2014-06-18 2023-10-31 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Car-expressing nk-92 cells as cell therapeutic agents
US20170274014A1 (en) * 2014-07-21 2017-09-28 Jennifer Brogdon Combinations of low, immune enhancing, doses of mtor inhibitors and cars
GB201501175D0 (en) * 2015-01-23 2015-03-11 Univ Oslo Hf A universal T-cell for personalised medicine

Also Published As

Publication number Publication date
EP3247791A1 (en) 2017-11-29
PL3247791T3 (pl) 2022-09-05
CA2973924C (en) 2024-06-04
CN107250351A (zh) 2017-10-13
JP2018512047A (ja) 2018-05-10
BR112017015631A2 (pt) 2018-03-13
NZ733855A (en) 2023-10-27
KR20170121178A (ko) 2017-11-01
KR102479118B1 (ko) 2022-12-16
JP6899333B2 (ja) 2021-07-07
GB201501175D0 (en) 2015-03-11
IL253464B (en) 2022-04-01
EA201791381A1 (ru) 2018-02-28
AU2022200126A1 (en) 2022-02-10
IL253464A0 (en) 2017-09-28
DK3247791T3 (da) 2022-07-11
CA2973924A1 (en) 2016-07-28
AU2016208475B2 (en) 2021-10-14
MX2017009459A (es) 2018-04-11
SG11201705693XA (en) 2017-08-30
AU2016208475A1 (en) 2017-08-03
EP4095239A1 (en) 2022-11-30
US20180010097A1 (en) 2018-01-11
ES2922231T3 (es) 2022-09-12
EP3247791B1 (en) 2022-05-04
WO2016116601A1 (en) 2016-07-28
US20220127574A1 (en) 2022-04-28
US11155786B2 (en) 2021-10-26
PT3247791T (pt) 2022-07-20

Similar Documents

Publication Publication Date Title
MX390756B (es) Célula t asesina universal
BR112019007100A2 (pt) composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
CO2017003408A2 (es) Anticuerpos y fragmentos de los mismos como agonistas de gitr
PH12018501291A1 (en) Group b adenovirus encoding an anti-tcr-complex antibody or fragment
BR112016020287A2 (pt) células resistentes a vírus e usos das mesmas
BR112018008442A2 (pt) receptores quiméricos contendo domínios induto-res de traf e composições e métodos relacionados
EA201691631A1 (ru) Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции
MX2023001226A (es) Anticuerpos anti-lag-3.
PH12018502601A1 (en) Anti-b7-h3 antibodies and antibody drug conjugates
CL2020001181A1 (es) Nuevos receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos.
CR20200471A (es) PÉPTIDOS Y COMBINACIÒN DE PÉPTIDOS NOVEDOSOS PARA SU USO EN INMUNOTERAPIA CONTRA DIVERSOS TUMORES (Divisional 2017-0522)
HK1255161A1 (zh) 用於过继性细胞治疗的工程细胞
BR112018007206A2 (pt) peptídeos e combinações de peptídeos para uso em imunoterapia contra leucemia linfocítica crônica (cll) e outros cânceres
PH12018501335A1 (en) Novel generation of antigen-specific tcrs
BR112017017560A2 (pt) peptídeos e combinações de peptídeos para uso em imunoterapia do câncer de pulmão, incluindo cpcnp e outros câncere
MY192065A (en) Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof
EP4219725A3 (en) Altering gene expression in modified t cells and uses thereof
MX2020011788A (es) Acoplador trifuncional de antigeno de celulas t y metodos y usos del mismo.
BR112017008710A8 (pt) Composições e métodos para estimular a eficácia de imunoterapia celular adotiva
MX2017007138A (es) Metodos y composiciones para terapia celular adoptiva.
CN106714826A8 (zh) 用于减弱基因表达调节抗病毒转移载体免疫应答的方法和组合物
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
PH12018502402A1 (en) Methods of treating autoimmune disease using allogeneic t cells
AU2016335217A8 (en) Antigen receptors and uses thereof